1. Rapid Identification of Neutralizing Antibodies against SARS-CoV-2 Variants by mRNA Display
- Author
-
Tanaka, Shiho, Olson, C. Anders, Barnes, Christopher O., Higashide, Wendy, Gonzales, Marcos, Taft, Justin, Richardson, Ashley, Martin-Fernandez, Marta, Bogunovic, Dusan, Gnanapragasam, Priyanthi N. P., Bjorkman, Pamela J., Spilman, Patricia, Niazi, Kayvan, Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Tanaka, Shiho, Olson, C. Anders, Barnes, Christopher O., Higashide, Wendy, Gonzales, Marcos, Taft, Justin, Richardson, Ashley, Martin-Fernandez, Marta, Bogunovic, Dusan, Gnanapragasam, Priyanthi N. P., Bjorkman, Pamela J., Spilman, Patricia, Niazi, Kayvan, Rabizadeh, Shahrooz, and Soon-Shiong, Patrick
- Abstract
The increasing prevalence of SARS-CoV-2 variants with the ability to escape existing humoral protection conferred by previous infection and/or immunization necessitates the discovery of broadly-reactive neutralizing antibodies (nAbs). Utilizing mRNA display, we identified a set of antibodies against SARS-CoV-2 spike (S) proteins and characterized the structures of nAbs that recognized epitopes in the S1 subunit of the S glycoprotein. These structural studies revealed distinct binding modes for several antibodies, including targeting of rare cryptic epitopes in the receptor-binding domain (RBD) of S that interacts with angiotensin-converting enzyme 2 (ACE2) to initiate infection, as well as the S1 subdomain 1. A potent ACE2-blocking nAb was further engineered to sustain binding to S RBD with the E484K and L452R substitutions found in multiple SARS-CoV-2 variants. We demonstrate that mRNA display is a promising approach for the rapid identification of nAbs that can be used in combination to combat emerging SARS-CoV-2 variants.
- Published
- 2021